Supernus Free Cash Flow vs Inventory Turnover Analysis

SUPN Stock  USD 34.11  0.37  1.10%   
Supernus Pharmaceuticals financial indicator trend analysis is much more than just breaking down Supernus Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Supernus Pharmaceuticals is a good investment. Please check the relationship between Supernus Pharmaceuticals Free Cash Flow and its Inventory Turnover accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

Free Cash Flow vs Inventory Turnover

Free Cash Flow vs Inventory Turnover Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Supernus Pharmaceuticals Free Cash Flow account and Inventory Turnover. At this time, the significance of the direction appears to have strong relationship.
The correlation between Supernus Pharmaceuticals' Free Cash Flow and Inventory Turnover is 0.66. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Inventory Turnover in the same time period over historical financial statements of Supernus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Supernus Pharmaceuticals' Free Cash Flow and Inventory Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Supernus Pharmaceuticals are associated (or correlated) with its Inventory Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Inventory Turnover has no effect on the direction of Free Cash Flow i.e., Supernus Pharmaceuticals' Free Cash Flow and Inventory Turnover go up and down completely randomly.

Correlation Coefficient

0.66
Relationship DirectionPositive 
Relationship StrengthSignificant

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.
Most indicators from Supernus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 29th of March 2024, Issuance Of Capital Stock is likely to grow to about 8.4 M, while Selling General Administrative is likely to drop about 85.1 M.
 2021 2022 2023 2024 (projected)
Interest Expense23.4M7.1M2.4M2.3M
Depreciation And Amortization34.0M82.6M84.9M89.1M

Supernus Pharmaceuticals fundamental ratios Correlations

0.640.550.360.610.630.420.40.470.350.460.61-0.140.640.70.930.60.450.580.640.910.630.530.690.450.94
0.640.680.630.810.980.770.70.950.630.640.99-0.380.90.980.620.810.760.930.890.840.940.910.940.880.61
0.550.68-0.010.670.550.280.810.50.690.730.62-0.560.850.640.460.670.730.470.710.660.830.60.820.420.49
0.360.63-0.010.450.740.620.140.74-0.010.050.650.050.380.690.380.50.20.730.390.460.380.440.450.660.34
0.610.810.670.450.770.410.780.780.720.310.78-0.420.820.820.540.940.410.830.730.70.830.650.870.780.54
0.630.980.550.740.770.840.570.970.510.530.99-0.270.820.980.630.770.660.940.830.810.850.90.870.890.61
0.420.770.280.620.410.840.270.820.180.480.80.080.580.750.460.470.570.680.60.610.590.890.610.640.43
0.40.70.810.140.780.570.270.580.730.510.66-0.60.850.620.290.830.650.580.660.540.850.610.810.530.31
0.470.950.50.740.780.970.820.580.520.440.96-0.280.780.940.460.750.60.940.790.690.820.880.830.920.43
0.350.630.69-0.010.720.510.180.730.520.540.62-0.710.660.570.30.570.590.620.780.50.780.570.70.690.33
0.460.640.730.050.310.530.480.510.440.540.6-0.270.750.580.470.360.910.350.680.640.740.640.70.350.51
0.610.990.620.650.780.990.80.660.960.620.6-0.380.860.980.60.770.750.940.890.820.910.920.910.90.59
-0.14-0.38-0.560.05-0.42-0.270.08-0.6-0.28-0.71-0.27-0.38-0.38-0.31-0.12-0.34-0.46-0.4-0.6-0.29-0.52-0.29-0.42-0.45-0.14
0.640.90.850.380.820.820.580.850.780.660.750.86-0.380.870.610.880.790.720.820.830.960.80.980.660.62
0.70.980.640.690.820.980.750.620.940.570.580.98-0.310.870.660.790.680.930.860.850.890.850.920.880.66
0.930.620.460.380.540.630.460.290.460.30.470.6-0.120.610.660.570.440.540.660.930.580.530.660.430.99
0.60.810.670.50.940.770.470.830.750.570.360.77-0.340.880.790.570.460.760.670.730.830.660.890.670.56
0.450.760.730.20.410.660.570.650.60.590.910.75-0.460.790.680.440.460.530.820.690.850.760.780.520.45
0.580.930.470.730.830.940.680.580.940.620.350.94-0.40.720.930.540.760.530.820.730.810.80.810.970.53
0.640.890.710.390.730.830.60.660.790.780.680.89-0.60.820.860.660.670.820.820.850.930.830.890.830.64
0.910.840.660.460.70.810.610.540.690.50.640.82-0.290.830.850.930.730.690.730.850.830.750.870.640.92
0.630.940.830.380.830.850.590.850.820.780.740.91-0.520.960.890.580.830.850.810.930.830.840.980.770.59
0.530.910.60.440.650.90.890.610.880.570.640.92-0.290.80.850.530.660.760.80.830.750.840.820.770.53
0.690.940.820.450.870.870.610.810.830.70.70.91-0.420.980.920.660.890.780.810.890.870.980.820.750.66
0.450.880.420.660.780.890.640.530.920.690.350.9-0.450.660.880.430.670.520.970.830.640.770.770.750.42
0.940.610.490.340.540.610.430.310.430.330.510.59-0.140.620.660.990.560.450.530.640.920.590.530.660.42
Click cells to compare fundamentals

Supernus Pharmaceuticals Account Relationship Matchups

Supernus Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding53.8M53.7M54.4M61.7M55.5M42.6M
Total Assets1.2B1.5B1.7B1.7B1.4B1.5B
Short Long Term Debt Total375.6M390.3M420.6M438.0M41.5M39.5M
Other Current Liab3.2M40.0M65.0M139.8M279.9M293.9M
Total Current Liabilities160.6M245.1M315.4M688.0M290.2M154.7M
Total Stockholder Equity595.4M744.9M815.9M886.2M921.5M967.6M
Property Plant And Equipment Net38.3M37.8M17.0M15.2M42.5M44.7M
Net Debt194.2M101.7M217.1M344.8M(33.5M)(31.9M)
Retained Earnings199.5M326.5M379.9M481.2M482.6M506.7M
Accounts Payable10.1M78.9M117.7M96.3M2.0M1.9M
Cash181.4M288.6M203.4M93.1M75.1M116.1M
Non Current Assets Total687.6M873.7M1.1B968.4M915.9M961.7M
Non Currrent Assets Other615K8.0M(36.1M)(10.0M)8.5M8.9M
Cash And Short Term Investments347.1M422.5M339.7M461.3M254.9M201.2M
Net Receivables87.3M140.9M148.9M165.5M144.2M151.4M
Common Stock Total Equity51K52K53K54K62.1K40.8K
Short Term Investments165.7M133.9M136.2M368.2M179.8M98.1M
Liabilities And Stockholders Equity1.2B1.5B1.7B1.7B1.4B1.5B
Non Current Liabilities Total404.3M514.1M557.9M128.3M197.3M179.2M
Inventory26.6M48.3M86.0M91.5M77.4M81.3M
Other Current Assets11.6M18.7M27.0M15.8M16.7M8.5M
Other Stockholder Equity388.4M409.3M434.3M408.1M439.5M279.8M
Total Liab564.9M759.2M873.3M816.3M487.5M333.9M
Property Plant And Equipment Gross38.3M37.8M33.4M28.2M28.9M30.4M
Total Current Assets472.6M630.4M601.6M734.2M493.1M305.3M
Accumulated Other Comprehensive Income7.4M9.0M1.5M(3.2M)(593K)(563.4K)
Intangible Assets24.8M442.3M784.7M702.5M599.9M629.9M
Common Stock51K52K53K54K55K42.0K
Other Liab28.7M123.8M137.4M92.3M106.2M111.5M
Other Assets32.7M259.7M13.9M10.9M12.5M11.9M
Long Term Debt329.5M345.2M361.8M379.3M436.1M457.9M
Property Plant Equipment17.1M37.8M52.3M44.1M50.7M53.2M
Net Tangible Assets570.6M302.6M(86.4M)66.7M76.7M72.9M
Good Will24.8M77.9M117.5M117.0M134.6M141.3M
Retained Earnings Total Equity199.5M326.5M379.9M481.2M553.4M581.1M
Capital Surpluse388.4M409.3M434.3M408.1M469.3M352.1M

Supernus Pharmaceuticals Investors Sentiment

The influence of Supernus Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Supernus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Supernus Pharmaceuticals' public news can be used to forecast risks associated with an investment in Supernus. The trend in average sentiment can be used to explain how an investor holding Supernus can time the market purely based on public headlines and social activities around Supernus Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Supernus Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Supernus Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Supernus Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Supernus Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Supernus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Supernus Pharmaceuticals' short interest history, or implied volatility extrapolated from Supernus Pharmaceuticals options trading.

Currently Active Assets on Macroaxis

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for Supernus Stock analysis

When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.96)
Earnings Share
0.02
Revenue Per Share
11.14
Quarterly Revenue Growth
(0.02)
Return On Assets
0.0056
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.